Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Pancreatic Ductal Adenocarcinoma-Pipeline Review, H1 2015

Pancreatic Ductal Adenocarcinoma-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Pancreatic Ductal Adenocarcinoma-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Pancreatic Ductal Adenocarcinoma-Pipeline Review, H1 2015', provides an overview of the Pancreatic Ductal Adenocarcinoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pancreatic Ductal Adenocarcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatic Ductal Adenocarcinoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Pancreatic Ductal Adenocarcinoma

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Pancreatic Ductal Adenocarcinoma and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Pancreatic Ductal Adenocarcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Pancreatic Ductal Adenocarcinoma pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Pancreatic Ductal Adenocarcinoma

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Pancreatic Ductal Adenocarcinoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Pancreatic Ductal Adenocarcinoma Overview 8

Therapeutics Development 9

Pipeline Products for Pancreatic Ductal Adenocarcinoma-Overview 9

Pipeline Products for Pancreatic Ductal Adenocarcinoma-Comparative Analysis 10

Pancreatic Ductal Adenocarcinoma-Therapeutics under Development by Companies 11

Pancreatic Ductal Adenocarcinoma-Therapeutics under Investigation by Universities/Institutes 13

Pancreatic Ductal Adenocarcinoma-Pipeline Products Glance 14

Clinical Stage Products 14

Early Stage Products 15

Pancreatic Ductal Adenocarcinoma-Products under Development by Companies 16

Pancreatic Ductal Adenocarcinoma-Products under Investigation by Universities/Institutes 17

Pancreatic Ductal Adenocarcinoma-Companies Involved in Therapeutics Development 18

Centrose Llc 18

Clovis Oncology, Inc. 19

F. Hoffmann-La Roche Ltd. 20

FibroGen, Inc. 21

Gilead Sciences, Inc. 22

Incuron, LLC 23

InvivoGen Therapeutics 24

Medisyn Technologies, Inc. 25

Merck & Co., Inc. 26

Nerviano Medical Sciences S.r.l. 27

OncoMed Pharmaceuticals, Inc. 28

Pfizer Inc. 29

SillaJen Co. Ltd. 30

Pancreatic Ductal Adenocarcinoma-Therapeutics Assessment 31

Assessment by Monotherapy Products 31

Assessment by Target 32

Assessment by Mechanism of Action 34

Assessment by Route of Administration 36

Assessment by Molecule Type 38

Drug Profiles 40

CBL-0137-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

CYL-02-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

demcizumab-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

EDC-1-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

FG-3019-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

Hu-5F9G4-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

ipafricept-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

JX-929-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

MK-0752-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

MK-8628-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

momelotinib-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

MRK-003-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

MT-477-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

NMSP-715-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

PF-03084014-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

PSL-001-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

RG-7787-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

rucaparib phosphate-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

SiG12D-LODER-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

Small Molecule to Inhibit Wnt Signal and eIF5A for Pancreatic Cancer-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

Small Molecules to Modulate GLT-1 for Pancreatic Ductal Adenocarcinoma-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

vantictumab-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

Pancreatic Ductal Adenocarcinoma-Recent Pipeline Updates 76

Pancreatic Ductal Adenocarcinoma-Dormant Projects 98

Pancreatic Ductal Adenocarcinoma-Discontinued Products 99

Pancreatic Ductal Adenocarcinoma-Product Development Milestones 100

Featured News & Press Releases 100

Jun 25, 2013: Cleveland BioLabs And Incuron Announce Poster Presentation At ESMO 15th World Congress On Gastrointestinal Cancer 100

Appendix 101

Methodology 101

Coverage 101

Secondary Research 101

Primary Research 101

Expert Panel Validation 101

Contact Us 101

Disclaimer 102

List of Tables

Number of Products under Development for Pancreatic Ductal Adenocarcinoma, H1 2015 9

Number of Products under Development for Pancreatic Ductal Adenocarcinoma-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 12

Number of Products under Investigation by Universities/Institutes, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Comparative Analysis by Early Stage Development, H1 2015 15

Products under Development by Companies, H1 2015 16

Products under Investigation by Universities/Institutes, H1 2015 17

Pancreatic Ductal Adenocarcinoma-Pipeline by Centrose Llc, H1 2015 18

Pancreatic Ductal Adenocarcinoma-Pipeline by Clovis Oncology, Inc., H1 2015 19

Pancreatic Ductal Adenocarcinoma-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 20

Pancreatic Ductal Adenocarcinoma-Pipeline by FibroGen, Inc., H1 2015 21

Pancreatic Ductal Adenocarcinoma-Pipeline by Gilead Sciences, Inc., H1 2015 22

Pancreatic Ductal Adenocarcinoma-Pipeline by Incuron, LLC, H1 2015 23

Pancreatic Ductal Adenocarcinoma-Pipeline by InvivoGen Therapeutics, H1 2015 24

Pancreatic Ductal Adenocarcinoma-Pipeline by Medisyn Technologies, Inc., H1 2015 25

Pancreatic Ductal Adenocarcinoma-Pipeline by Merck & Co., Inc., H1 2015 26

Pancreatic Ductal Adenocarcinoma-Pipeline by Nerviano Medical Sciences S.r.l., H1 2015 27

Pancreatic Ductal Adenocarcinoma-Pipeline by OncoMed Pharmaceuticals, Inc., H1 2015 28

Pancreatic Ductal Adenocarcinoma-Pipeline by Pfizer Inc., H1 2015 29

Pancreatic Ductal Adenocarcinoma-Pipeline by SillaJen Co. Ltd., H1 2015 30

Assessment by Monotherapy Products, H1 2015 31

Number of Products by Stage and Target, H1 2015 33

Number of Products by Stage and Mechanism of Action, H1 2015 35

Number of Products by Stage and Route of Administration, H1 2015 37

Number of Products by Stage and Molecule Type, H1 2015 39

Pancreatic Ductal Adenocarcinoma Therapeutics-Recent Pipeline Updates, H1 2015 76

Pancreatic Ductal Adenocarcinoma-Dormant Projects, H1 2015 98

Pancreatic Ductal Adenocarcinoma-Discontinued Products, H1 2015 99

List of Figures

Number of Products under Development for Pancreatic Ductal Adenocarcinoma, H1 2015 9

Number of Products under Development for Pancreatic Ductal Adenocarcinoma-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Number of Products under Investigation by Universities/Institutes, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Comparative Analysis by Early Stage Products, H1 2015 15

Assessment by Monotherapy Products, H1 2015 31

Number of Products by Top 10 Targets, H1 2015 32

Number of Products by Stage and Top 10 Targets, H1 2015 32

Number of Products by Top 10 Mechanism of Actions, H1 2015 34

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 34

Number of Products by Top 10 Routes of Administration, H1 2015 36

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 37

Number of Products by Top 10 Molecule Types, H1 2015 38

Number of Products by Stage and Top 10 Molecule Types, H1 2015 39

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Centrose Llc

Clovis Oncology, Inc.

F. Hoffmann-La Roche Ltd.

FibroGen, Inc.

Gilead Sciences, Inc.

Incuron, LLC

InvivoGen Therapeutics

Medisyn Technologies, Inc.

Merck & Co., Inc.

Nerviano Medical Sciences S.r.l.

OncoMed Pharmaceuticals, Inc.

Pfizer Inc.

SillaJen Co. Ltd.

Pancreatic Ductal Adenocarcinoma Therapeutic Products under Development, Key Players in Pancreatic Ductal Adenocarcinoma Therapeutics, Pancreatic Ductal Adenocarcinoma Pipeline Overview, Pancreatic Ductal Adenocarcinoma Pipeline, Pancreatic Ductal Adenocarcinoma Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com